Reflections from the AVAC Webinar: The Scientific Journey of Lenacapavir – What’s Next for Zambia?

Yesterday, I had the privilege of joining AVAC ’s webinar, “The Scientific Journey of Lenacapavir: From Basic Science to Clinical Development to Impact.” The session traced the evolution of Lenacapavir (LEN) from early-stage discovery to its promise as a long-acting HIV prevention tool—a potential game-changer in the global HIV response.

The timing of this discussion couldn’t be more relevant for Zambia. As we advance our own PrEP journey, it was encouraging to hear that Zambia recorded the second-highest number of PrEP initiations in Sub-Saharan Africa as of November 2024 (AVAC). This reflects years of deliberate investment, community trust, and sustained health system strengthening.

Now, we stand at the threshold of a new chapter. The U.S. FDA is set to review LEN for HIV prevention on June 19, with WHO guidance likely to follow. As shared in the webinar, Gilead has committed to making 10 million doses of LEN available globally—a critical opportunity to expand access. However, these doses were expected to be procured through USAID and the Global Fund, both of which now face mounting funding constraints.

For Zambia, this means confronting not just regulatory readiness and delivery logistics, but also the broader challenge of sustaining PrEP access in a volatile financing environment. As newer, high-impact products like LEN emerge, we must rethink our approach to co-financing, prioritisation, and procurement if we are to stay on course.

Paraphrasing Linda-Gail Bekker equity must lead the way. LEN cannot become another innovation that is out of reach for the communities who need it most. Its distribution must prioritise high-burden countries, such as Zambia, and the young people who continue to face the highest risk.

At Tiko we remain steadfast in our commitment to HIV prevention. We will continue partnering with government, communities, and the global health ecosystem to ensure that every new innovation—including LEN—is met with the readiness, resolve, and responsibility it demands.